Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study
Open Access
- 1 February 2006
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 65 (2), 257-260
- https://doi.org/10.1136/ard.2005.039099
Abstract
Objective: To describe the efficacy and safety of adalimumab in patients with rheumatoid arthritis (RA) who had previously discontinued infliximab treatment. Methods: 24 patients with RA who discontinued treatment with infliximab (switchers) were treated with adalimumab (40 mg every 2 weeks, subcutaneously) for 12 months. The results were compared with those for 25 patients with RA receiving adalimumab who had not previously used an anti-tumour necrosis factor α inhibitor (controls). Disease activity was measured with the 28 joint count Disease Activity Score (DAS28), and clinical response with the American College of Rheumatology (ACR) 20% response criteria. Results: At baseline there were no differences in demographic, clinical, and laboratory features between the two groups. After 12 months’ adalimumab treatment, clinical improvement was similar in both groups. More specifically, ACR 20% response criteria were achieved by 18/24 (75%) switchers and by 19/25 (76%) subjects in the control group. Four switchers discontinued the study—two because of adverse events and two because of lack of efficacy, while three control patients discontinued the study—one because of lack of efficacy and two owing to side effects. Conclusion: Adalimumab is a well tolerated and effective treatment for patients with RA, even when infliximab has been discontinued.Keywords
This publication has 16 references indexed in Scilit:
- Infliximab therapy in established rheumatoid arthritis: An observational studyAmerican Journal Of Medicine, 2005
- Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept.2004
- An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Prior Loss of Response or Intolerance to Infliximab for Crohn's DiseaseThe American Journal of Gastroenterology, 2004
- The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis.2004
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving MethotrexateNew England Journal of Medicine, 1999
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- Analysis of improvement in individual rheumatoid arthritis patients treated with disease‐modifying antirheumatic drugs, based on the findings in patients treated with placeboArthritis & Rheumatism, 1990
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988